INVERSE AGONISTS: MORE THAN JUST ANTAGONISTS?
Abstract
This review presents information on pharmaceuticals that have the properties of inverse agonists. The article describes the features of the interaction of the ligand - receptor with constitutive conformational changes. Many of ligands, assumed to be neutral antagonists, behave as inverse agonists displaying negative efficacy in experimental systems. This suggests that their therapeutic actions may involve not only receptor blockade, but also the decrease of spontaneous receptor activity. Examples of inverse agonists that influence the processes of excitation of adrenergic, histaminergic, opioid and benzodiazepine receptors are presented. The existence of constitutive activity in vivo and its pathophysiological relevance are also discussed
About the Authors
R. N. Alyautdin
Scientific Centre for Expert Evaluation of Medicinal Products Russian Federation
Russian Federation
Russian Federation
B. K. Romanov
Scientific Centre for Expert Evaluation of Medicinal Products Russian Federation
Russian Federation
Russian Federation
References
1. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety//. Diabetes Metab. J. 2012.V.36. P.13–25.
2. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrié P. CB1 cann abinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity//. J. Obes. Rela.t Metab. Disord. 2004. V.28. P.640–648.
3. Pang Z, Wu NN, Zhao W, Chain DC, Schaffer E, Zhang X. The central cann abinoid CB1 receptor is required for diet-induced obesity and rimon abant's antiobesity effects in mice// Obesity (Silver Spring). 2011. V.19. P.1923–1934.
4. Can als M, Milligan G. Constitutive activity of the cann abinoid CB1 receptor regulates the function of co-expressed mu opioid receptors// J. Biol.Chem. 2008.V. 283. P. 11424 –1134.
5. Khilin ani G., Khilin ani A.G. Inverse agonism and its therapeutic significance// Indian J. Pharmacol. 2011.V. 43. P. 492–501.
6. Burgissert E, De Leans A, Lefkowitz RJ. Reci procal modulation of agonist and antagonist binding to muscarinic cholinergic receptor by guanine nucleotide// Proc. Natl Acad. Sci. USA. V. 79. P. 1732–1736.
7. Braestrup C, Schmiechen R, Neef G, Nielsen RA, and Petersen EN (1982) Interactionof convulsive ligands with benzodiazepine receptors// Science. V. 216. P.1241–1243.
8. File SE, Lister RG, Nutt DJ. The anxiogenic action of benzodiazepine antagonists// Neuropharmacology. 1982. V.21.P. 1033–1037.
9. Costa Т, Herz A. Antagonists with negative intrinsic activity at 6 opioid receptors coupled to GTP-binding proteins// Proc. Natl. Acad. Sci. USA.1986. V. 86. P. 7321–7325.
10. Leurs R, Church MK, Taglialatela M. H1-antihistamines: Inverse agonism, anti-inflammatory actions and cardiac effects. Clin. Exp. Allergy. 2002. V.32. P.489–498.
11. Murphy JM, Jackie J, Mellor-Burke J, Lumeng L, Li T. BDZ inverse agonist RO15-4513 exerts prolonged and selective suppression of ethanol intake in alcohol preferring rats//
12. Psychopharmacology. 1994. V.115. P. 325–31.
13. Purohit A, Smith C, Herrick-Davis K, Teitler M. Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: Inverse agonist activity of anti psychotic drugs// Psychopharmacology (Berl). 2005. V.179. P. 461–469.
14. Maximino C, Puty B, Benzecry R, Araújo J, Lima MG, de Jesus Oliveira B. Role of serotonin in zebrafish (Danio rerio) anxiety: relationshi p with serotonin levels and effect of
15. buspirone, WAY 100635, SB 224289, fluoxetine and para-chlorophenylalanine (pCPA) in two behavioral models// Neuropharmacology. 2013. V.71.P. 83–97.
16. Yasuda N, Akazawa H, Qin Y, Zou Y, Komuro I. A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II// Naunyn Schmiedebergs Arch. Pharmacol. 2008. V.377. P. 393–399.
17. Zhang F, Steinberg SF. S49G and R389G polymorphisms of the β-adrenergic receptor influence sign aling via the cAMP-PKA and ERK pathways Physiol. Genomics. 2013. V.45. P. 1186–1192.
18. Nguyen LP, Omoluabi O, Parra S, Joann a M, Frieske JM, Clement C, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content in a murine asthma model// Am. J. Respir. Cell Mol. Biol. 2008. V.38. P.256–262.
Review
For citations:
Alyautdin R.N., Romanov B.K. INVERSE AGONISTS: MORE THAN JUST ANTAGONISTS? Safety and Risk of Pharmacotherapy. 2014;(4):6-11. (In Russ.)
Views:
782
Email this article 